Vitamin D may slow progression of low-grade prostate tumors
the ONA take:
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery, new research presented at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver, Colorado has shown.
For the randomized, controlled clinical trial, researchers assigned 37 men with low-grade prostate cancer undergoing elective prostatectomies to receive either 4,000U of vitamin D daily or placebo during the 60-day waiting period prior to surgery. The patients' prostate glands were then removed and examined.
Results showed that men who received vitamin D showed improvements in their prostate tumors while those in the placebo group experienced no changes or their tumors got worse.
The findings suggest that vitamin D supplementation, well below pharmacological levels, may improve less aggressive prostate cancer by decreasing inflammation. It is not clear yet whether vitamin D prevents or treats prostate cancer, but it can prevent lower-grade tumors from becoming aggressive.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|